Five Prime Therapeutics Promotes Aron Knickerbocker to CEO

Five Prime Therapeutics (NASDAQ: [[ticker:FPRX]]) did not have to go far to find its next CEO. Aron Knickerbocker, currently the chief operating officer of the South San Francisco, CA, biotech, has been named its new CEO. Knickerbocker will succeed Lewis “Rusty” Williams, who will become executive chairman. The change will become effective Jan. 1. Knickerbocker first joined Five Prime in 2009. His experience also includes posts at ALZA Corporation, Amgen (NASDAQ: [[ticker:AMGN]]), and Genentech.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan